miR-34a inhibits breast cancer stemness and increases the chemosensitivity to doxorubicin and paclitaxel partially by downregulating the Notch1 pathway, with reduced CD44+/CD24– BCSCs and CSC marker ALDH1 (Park et al., 2014; Kang et al., 2015). This evidence concerns the gene CD44 and breast carcinoma.